Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 87

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 87
---
 EP, FR, GB, HK, IE, JP, NL, NO, SE, US     Issued 05/02/2017Issued 06/16/2020 pending 
     
           5/19/20365/19/20365/19/2036 
     
    Use CompositionComposition/use

    Modified mRNA for Multicell Transformation
     
    Next generation cancer vaccine using mRNA encoding a bacterial antigen to prime anti- cancer immune responses  
    PCT/US2021/031204 (WO 2021/226413)
    5/7/2021
    Nationalized in CN, JP, CA, IN, AU, EP, KR To be filed in HK
    5/7/2041

    Exosome Delivery of Cancer Therapeutics
     
    Production and use of exosome preparations to systemically deliver pDNA and/or mRNA tumors
    US 18/055,724(US 2023-0183690) 
    11/15/2022
    Published/pending
     
    Composition/use

Employees and Human Capital Resources

As of December 31, 2024, we had 19 full-time employees and no part-time employees. Of these employees, 15 were engaged in research and development activities. The majority of our employees are based in Tampa, Florida. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.

Government Regulation and Product Approval

Therapeutic products are subject to rigorous regulation by the FDA and other governmental agency regulations in the United States and in foreign countries. Noncompliance with applicable requirements can result in import detentions, fines, civil monetary penalties, injunctions, suspensions or losses of regulatory approvals or licenses, recall or seizure of products, operating restrictions, denial of export applications, governmental prohibitions on entering into supply contracts, and criminal penalties and prosecution. Failure to obtain regulatory approvals or the restriction, suspension or revocation of regulatory